GRAIL publication uses Streck tube
Streck’s Cell-Free DNA BCT® was used in a groundbreaking research study detailing the early detection of cancer utilizing a blood draw. Research by GRAIL, an industry leader working toward early cancer detection, was recently published in an article titled “Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA” in the Annals of Oncology.
GRAIL believes earlier cancer detection will lead to better clinical outcomes and greater rates of survival. In the study, GRAIL utilized a specific set of over 100,000 methylation markers. The performance of their assay and the methylation pattern allowed for detection of more than 50 cancer types across all clinical stages. GRAIL’s testing in the article relied on both whole-genome bisulfite sequencing and whole-genome sequencing from cell-free DNA and genomic white blood cell DNA isolated from patient blood samples.
All blood draws referenced in the publication were collected in Streck Cell-Free DNA BCTs. Eight or four 10 mL Cell-Free DNA BCTs were drawn per patient at participating sites and shipped to a central lab for processing and analysis. The tubes maintained the integrity of the patient samples during shipping, and upon receipt the aforementioned targets of interest were harvested for future analysis. The cell-free DNA, White Blood Cell DNA and orthogonal cancer tissue DNA were compared using GRAIL’s screening methodology.
Cell-Free DNA BCT is a direct draw blood collection tube that stabilizes cell-free DNA for up to 14 days at 6 °C to 37 °C and CTCs for up to 7 days at 15 °C to 30 °C. Once isolated from stored plasma, the cfDNA and CTCs are suitable for many downstream applications used in clinical research studies, drug discovery and diagnostic assay development.
Cell Free-DNA BCT is for Research Use Only. Not for use in diagnostic procedures in the U.S. A CE version of these tubes is also available. Cell-Free DNA BCT CE is for Export Only. Not for sale in the U.S.